Profile data is unavailable for this security.
About the company
Zimmer Biomet Holdings, Inc. is a global medical technology company. Its segments include Americas, EMEA, and Asia Pacific. The Company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic (CMFT) products; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its other product category primarily includes its robotic, surgical and bone cement products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee, and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System, and G7 Acetabular System. Its S.E.T. product category includes sports medicine, biologics, foot and others.
- Revenue in USD (TTM)7.45bn
- Net income in USD963.80m
- Incorporated2001
- Employees18.00k
- LocationZimmer Biomet Holdings Inc345 E Main StWARSAW 46580-2746United StatesUSA
- Phone+1 (574) 267-6131
- Fax+1 (302) 636-5454
- Websitehttps://www.zimmerbiomet.com/en
Mergers & acquisitions
| Acquired company | ZBH:NYQ since announced | Transaction value |
|---|---|---|
| Video Interventionelle Medicale Scientifique SAS | -9.89% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Insulet Corp | 1.78bn | 234.00m | 11.96bn | 3.00k | 53.17 | 15.12 | 38.79 | 6.72 | 3.21 | 3.21 | 23.61 | 11.29 | 0.7249 | 1.36 | 6.62 | 593,566.70 | 9.53 | 2.71 | 11.42 | 3.14 | 68.86 | 65.81 | 13.14 | 4.28 | 2.75 | 65.58 | 0.6393 | 0.00 | 30.02 | 24.66 | 4,384.78 | 128.77 | -7.63 | -- |
| Shockwave Medical Inc | 787.97m | 163.50m | 12.54bn | 1.47k | 78.29 | 16.26 | 71.57 | 15.92 | 4.27 | 4.27 | 20.58 | 20.55 | 0.6493 | 1.05 | 7.55 | 536,763.60 | 13.47 | 10.29 | 14.91 | 11.39 | 86.99 | 84.69 | 20.75 | 15.14 | 12.61 | -- | 0.4936 | 0.00 | 49.11 | 126.45 | -31.81 | -- | 72.88 | -- |
| Hologic Inc | 3.96bn | 466.50m | 17.27bn | 6.99k | 38.06 | 3.56 | 21.99 | 4.36 | 1.94 | 1.94 | 16.30 | 20.76 | 0.4361 | 2.66 | 5.82 | 566,609.40 | 5.14 | 11.40 | 5.74 | 13.38 | 55.12 | 60.29 | 11.78 | 20.95 | 3.29 | -- | 0.3465 | 0.00 | -17.12 | 4.61 | -64.98 | -- | 7.30 | -- |
| Baxter International Inc | 14.89bn | -38.00m | 17.33bn | 60.00k | -- | 2.12 | 13.87 | 1.16 | -0.0762 | 5.21 | 29.33 | 16.04 | 0.5311 | 3.21 | 5.71 | 248,200.00 | -0.107 | 0.1942 | -0.1338 | 0.2333 | 36.31 | 38.20 | -0.2015 | 0.3674 | 1.01 | 3.58 | 0.625 | 1,398.94 | 2.12 | 5.94 | 97.15 | -- | 0.982 | 9.71 |
| Cooper Companies Inc | 3.67bn | 290.80m | 18.77bn | 15.00k | 95.44 | 2.44 | 28.20 | 5.12 | 0.9896 | 0.9896 | 7.36 | 38.73 | 0.3108 | 1.77 | 5.95 | 244,420.00 | 2.47 | 10.06 | 2.68 | 11.34 | 66.09 | 65.54 | 7.93 | 29.00 | 1.08 | 4.92 | 0.2649 | 0.3469 | 8.61 | 7.24 | -23.74 | -3.66 | 15.18 | 31.95 |
| Align Technology, Inc. | 3.92bn | 462.28m | 19.00bn | 21.61k | 41.58 | 5.05 | 31.57 | 4.85 | 6.07 | 6.07 | 51.44 | 49.94 | 0.6497 | 3.96 | 4.27 | 181,237.60 | 7.67 | 16.34 | 11.51 | 24.14 | 70.06 | 71.72 | 11.80 | 23.16 | 1.09 | -- | 0.00 | 0.00 | 3.42 | 14.45 | 23.09 | 2.15 | -4.46 | -- |
| Steris PLC | 5.44bn | 532.54m | 22.41bn | 17.00k | 42.25 | 3.55 | 27.60 | 4.12 | 5.37 | 3.81 | 54.85 | 63.91 | 0.4971 | 4.51 | 5.62 | -- | 4.88 | 4.03 | 5.32 | 4.41 | 43.23 | 43.50 | 9.82 | 8.20 | 2.34 | 8.76 | 0.3307 | 47.34 | 3.65 | 13.06 | 415.22 | 12.67 | 13.69 | 8.83 |
| Zimmer Biomet Holdings Inc | 7.45bn | 963.80m | 23.83bn | 18.00k | 25.08 | 1.89 | 12.39 | 3.20 | 4.62 | 4.62 | 35.72 | 61.24 | 0.3491 | 0.9052 | 5.27 | 414,027.80 | 4.52 | 2.21 | 5.14 | 2.52 | 71.89 | 71.25 | 12.95 | 7.28 | 0.802 | 7.32 | 0.315 | 38.90 | 6.55 | -1.40 | 252.86 | -- | 9.44 | 0.00 |
| West Pharmaceutical Services Inc. | 2.93bn | 568.70m | 23.94bn | 10.60k | 43.32 | 8.95 | 34.50 | 8.17 | 7.58 | 7.58 | 39.09 | 36.72 | 0.7995 | 4.20 | 5.65 | 276,283.00 | 15.08 | 15.61 | 17.99 | 18.65 | 37.15 | 38.06 | 18.86 | 18.47 | 1.95 | -- | 0.0714 | 10.69 | 2.18 | 11.43 | 2.28 | 23.76 | 28.16 | 6.20 |
| Resmed Inc | 4.58bn | 958.38m | 31.08bn | 10.14k | 32.57 | 6.71 | 27.31 | 6.78 | 6.50 | 6.50 | 31.07 | 31.52 | 0.6777 | 2.20 | 5.99 | 452,086.70 | 14.17 | 13.59 | 15.98 | 15.89 | 55.78 | 56.98 | 20.91 | 19.22 | 1.97 | 25.88 | 0.1786 | 36.66 | 18.02 | 12.53 | 15.15 | 14.63 | 13.40 | 4.68 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 22.88m | 11.16% |
| Dodge & Coxas of 31 Mar 2024 | 16.42m | 8.01% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 11.65m | 5.68% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 10.27m | 5.01% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 9.31m | 4.54% |
| American Century Investment Management, Inc.as of 31 Mar 2024 | 5.74m | 2.80% |
| PRIMECAP Management Co.as of 31 Mar 2024 | 5.06m | 2.47% |
| Invesco Advisers, Inc.as of 31 Mar 2024 | 5.02m | 2.45% |
| Geode Capital Management LLCas of 31 Mar 2024 | 4.75m | 2.32% |
| Boston Partners Global Investors, Inc.as of 31 Mar 2024 | 3.31m | 1.62% |
